Literature DB >> 15536688

Rash correlates with tumour response after cetuximab.

Ed Susman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15536688     DOI： 10.1016/s1470-2045(04)01627-4

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  7 in total

1.  [Cutaneous side effects of EGF-receptor inhibition and their management].

Authors:  R Gutzmer; T Werfel; A Kapp; J Elsner
Journal:  Hautarzt       Date:  2006-06       Impact factor: 0.751

2.  Chemotherapy and other systemic therapies for hepatocellular carcinoma and liver metastases.

Authors:  Kevin S Brown
Journal:  Semin Intervent Radiol       Date:  2006-03       Impact factor: 1.513

3.  Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib.

Authors:  Lokesh Jain; Tristan M Sissung; Romano Danesi; Elise C Kohn; William L Dahut; Shivaani Kummar; David Venzon; David Liewehr; Bevin C English; Caitlin E Baum; Robert Yarchoan; Giuseppe Giaccone; Jürgen Venitz; Douglas K Price; William D Figg
Journal:  J Exp Clin Cancer Res       Date:  2010-07-14

Review 4.  EGFR, HER2 and VEGF pathways: validated targets for cancer treatment.

Authors:  Michael F Press; Heinz-Josef Lenz
Journal:  Drugs       Date:  2007       Impact factor: 9.546

5.  Epidemiology of lung cancer prognosis: quantity and quality of life.

Authors:  Ping Yang
Journal:  Methods Mol Biol       Date:  2009

6.  Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash.

Authors:  Russell J Schilder; Harsh B Pathak; Anna E Lokshin; Robert W Holloway; Ronald D Alvarez; Carol Aghajanian; Hua Min; Karthik Devarajan; Eric Ross; Charles W Drescher; Andrew K Godwin
Journal:  Gynecol Oncol       Date:  2009-01-21       Impact factor: 5.482

7.  Docetaxel plus cetuximab as second-line treatment for docetaxel-refractory oesophagogastric cancer: the AGITG ATTAX2 trial.

Authors:  N C Tebbutt; M M Parry; D Zannino; A H Strickland; G A Van Hazel; N Pavlakis; V Ganju; D Mellor; A Dobrovic; V J Gebski
Journal:  Br J Cancer       Date:  2013-02-14       Impact factor: 7.640
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.